myomo
my own motion

INVESTOR PRESENTATION AUGUST 2026

Paul R. Gudonis, Chairman and CEO
David Henry, Chief Financial Officer

Conquering Upper Limb Paralysis with Wearable Medical Robotics

myomo
my own motion

Legal Disclaimer

This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Company's financial position and projections of future operating results, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company's management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and other factors. These risks and uncertainties include, among others, risks related to the Company's liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Investment Highlights

Created New Product Category for a Large, Unmet Need

First-Mover Advantage with Strong Competitive Position

Medicare Reimbursement and New Payer Contracts Expanding Patient Access

Growing Revenues from Recurring Patient Sources

Attractive Margin Profile with Opportunity for Scale Economics

Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease

Major Dx

- Stroke/CVA
- Traumatic Brain Injury
- Spinal Cord Injury
- Brachial Plexus Injury



Other Dx

- Cerebral Palsy
- Multiple Sclerosis
- ALS
- Spinal Muscular Atrophy
- Acute Flaccid Myelitis

Patient Journey: From Stroke to Rehab Therapy

ONSET	ACUTE CARE	SUB-ACUTE CARE	OUTPATIENT THERAPY (Incidence)	CHRONIC HEMIPARESIS (Prevalence)
Incidence: 800,000 Cases/Yr. in US	Onset → 1 week	1 week → 6 months	6–12 months	> 6–12 months

Patients are told “Get used to it – You’ll never use your arm and hand again for the rest of your life”

Substantial Market Opportunity

40,000 to 80,000 patients replenish the prevalence population each year



Annual Incidences



Prevalence Population

Senior Insured Population

46%
54%

Medicare Part B
Med. Advantage

Source: Kaiser Family Foundation

Source: Centers for Disease Control and Prevention, Christopher and Dana Reeve Foundation, Frontiers in Neurology, American Heart Association (*Stroke*) and Myomo base model estimates

Our Solution: The MyoPro Arm Brace -- Enabling Activities of Daily Living

How it Works: Myomo's Proprietary Technology

- ➢ **Brain-computer interface**
- ➢ **Interpret and amplify a patient's weak EMG signal**
- ➢ **35 Patents in U.S. and International markets valid through 2042.**



Massachusetts Institute of Technology

HARVARD MEDICAL SCHOOL

Myomo Mobility Platform: Technology and Commercial Infrastructure



Go to Market Approach Via 3 Distribution Channels

Direct-to-Patient Advertising (Social Media/TV)

Referrals from Rehab Hospitals (MyoConnect)



Orthotics & Prosthetics Clinics

------------ Recurring Patient Sources ------------

Insurance Reimbursement Supported by Clinical Research

myomo
my own motion

Medicare

UnitedHealthcare
Medicare Solutions

BlueCross BlueShield

GKV
Spitzenverband
German Statutory
Health Insurance

VA | U.S. Department of Veterans Affairs

Medicare Fee $68,800*



Subjects from our Patient Registry



Systematic review published in 2025

THE UNIVERSITY of UTAH

Randomized Controlled Trial underway

* Fee for MyoPro 2x Motion G

2026 Strategy Direction & Four Success Pillars

1. Shift to Recurring Patient Sources



2. Increase market access with additional payer contracts



3. Demonstrate operating leverage



Q2 2026:
Revenue ↑ 21%
Opex ↑ 1%
GM 63% → 72%

4. Invest in product development and research



Track Record: 10 Years of Revenue Growth



myomo my own motion

P&L and Key Balance Sheet Metrics

P&L

($000's)	Actual Q2'26	Actual Q2'25	Actual 2025	Actual 2024
Revenue	11,705	9,652	40,928	32,551
COGS	3,262	3,600	14,040	9,366
Gross Profit	8,443	6,052	26,888	23,185
Gross Margin	72.1%	62.7%	65.7%	71.2%
Operating Expenses:				
R&D	1,720	2,001	6,944	4,772
Selling, Clinincal & Mtkg	5,264	5,234	20,385	12,237
G&A	3,713	3,407	13,961	12,383
Total	10,697	10,642	41,290	29,392
Operating Loss	(2,254)	(4,590)	$ (14,402)	$ (6,207)
Interest expense (income)	536	(106)	451	(389)
Other (income) expense	1,200	-	217	-
Income Taxes	31	148	504	366
	1,767	42	1,172	(23)
Net Loss	$ (4,021)	$ (4,632)	$ (15,574)	$ (6,184)

Key Balance Sheet Metrics

($000's)	Actual Q2'26		Actual Q1'26
Cash & Investments	$ 13,452		$ 15,696
Working Capital	13,916		16,273
Debt	12,609	*	12,568
Shareholders' Equity	5,829		9,002
Shares Outstanding	43,298	**	42,330

* *Face value + accretion of final payment liability*

** *Includes unexercised pre-funded warrants*

Notes:
- Interest only on debt until May 2027
- Operating leverage in Q2 and YTD as guided
- Expect <$2M cash burn in total for 2H 2026

Where We're Headed: Longer-Term Vision



- > $100M in annual revenues
- 70% gross margin, positive EBITDA and cash flow.
- Durable business with recurring patient sources.
- Increased market access with improved reimbursement.
- Growth opportunities: New products, new indications, new markets.

Leadership Team & Board of Directors

Management Team Members

Paul R. Gudonis
Chairman & CEO
Scaled multiple tech co's, largest from $5M to $1.2B revenue (BBN/Genuity)

David Henry, CFO
Raised nearly $900M in capital for public companies

Micah Mitchell
Chief Commercial Officer
Grew sales 10x at several custom DME businesses

Dr. Harry Kovelman
Chief Medical Officer
Track record of expanding patent access for new technologies

Malcolm Bock
VP of Engineering and Product Strategy
Experienced Medical Device Engineering Executive

Galina Shtivelman
VP Human Resources
Leads efforts to scale human capital, talent acquisition and culture.

Dennis Shay Dir - QA/RA
Leads Quality and Regulatory Affairs efforts to enable global market access

John Frijters
Managing Director - International
Experienced executive O&P Europe – based



Kathy Sawyers, PT, ATP Sr. Dir. – Clinical Outcomes
Oversees clinician training and user support

Colin Anderson
Sr. Dir – Global Operations
Experienced at scaling operations in med device industry

Board of Directors

Thomas Kirk
Lead Independent Director
Former CEO, Hanger Clinics

Thomas Crowley
Board Member
Former Med Device CEO

Milton Morris
Board Member
Former President & CEO, Neuspera Medical; Boston Scientific exec

Heather Getz
Board Member
CEO and Director
TELA Bio

William Febbo
Board Member
CEO and Director
Performance Health Systems

Joseph Manko
Board Member
Senior Principal
Horton Capital Management

Thank You!

For Additional Information:

Paul R. Gudonis, CEO
paul@myomo.com
617-401-2623

David Henry, CFO
david.henry@myomo.com
508-344-5235